Exploring bone metabolism in women with premature ovarian insufficiency
Explore the Bone Metabolism Characteristics of Premature Ovarian Insufficiency
This study looks at how premature ovarian insufficiency affects bone health in women aged 18 to 39 by measuring certain bone markers and bone density.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 39 Years |
| Sex | Female |
| Sponsor | Dongzhimen Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06339489 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the characteristics of bone metabolism in women diagnosed with premature ovarian insufficiency. It focuses on measuring serum levels of specific bone metabolic markers, including TRACP-5b and BALP, as well as assessing bone mineral density (BMD) at various sites such as the lumbar spine and hip. The study aims to provide insights into how premature ovarian insufficiency affects bone health and metabolism. Participants will be women aged 18 to 39 who meet specific inclusion criteria and provide informed consent.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 to 39 diagnosed with premature ovarian insufficiency.
Not a fit: Patients with congenital gonadal dysplasia, a family history of early menopause, or those who have undergone ovarian surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of bone health in women with premature ovarian insufficiency, potentially leading to better management strategies.
How similar studies have performed: While this study explores a specific aspect of bone metabolism in a unique patient population, similar studies have shown varying degrees of success in understanding bone health in hormonal conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients diagnosed by Western medicine with premature ovarian insufficiency. 18 ≤ patients' age ≤ 39 years;. Patients who voluntarily participate in this study, sign an informed consent form. Exclusion Criteria: Patients with congenital gonadal dysplasia or a family history similar to "early menopause". POI patients with acquired organic lesions or ovarian surgery. Patients who have taken Western or herbal medicine artificial cycle therapy or other endocrine therapy in the past three months. Patients with serious primary diseases and mental disorders such as cardiovascular and cerebrovascular, liver, kidney and hematopoietic system. Patients who are breastfeeding or pregnant.
Where this trial is running
Beijing
- Dongzhimen Hospital, Beijing University of Chinese Medicine — Beijing, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.